{"id":1755,"date":"2014-03-17T13:01:42","date_gmt":"2014-03-17T13:01:42","guid":{"rendered":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?p=1755"},"modified":"2014-03-17T13:01:42","modified_gmt":"2014-03-17T13:01:42","slug":"eplerenon-neuer-therapiestandard-bei-herzinsuffizienz-nyha-ii","status":"publish","type":"post","link":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/eplerenon-neuer-therapiestandard-bei-herzinsuffizienz-nyha-ii\/","title":{"rendered":"Eplerenon: Neuer Therapiestandard bei Herzinsuffizienz NYHA II?"},"content":{"rendered":"<p>AMB 2011,\u00a045, 50 &nbsp; Eplerenon: Neuer Therapiestandard bei Herzinsuffizienz NYHA II? &nbsp; In der Entstehungskaskade der Herzinsuffizienz spielt der Hyperaldosteronismus eine zentrale Rolle. Eine Hemmung der Aldosteronwirkung bessert Belastbarkeit und Prognose herzinsuffizienter Patienten. \u00dcber den 2005 eingef\u00fchrten (selektiv an den Mineralokortikoid-Rezeptor bindenden) Aldosteron-Antagonisten Eplerenon (Inspra\u00ae; Pfizer) haben wir anl\u00e4sslich seiner Zulassung berichtet (1,\u00a02). Die Zulassungsstudie [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>AMB 2011,\u00a045, 50 &nbsp; Eplerenon: Neuer Therapiestandard bei Herzinsuffizienz NYHA II? &nbsp; In der Entstehungskaskade der Herzinsuffizienz spielt der Hyperaldosteronismus eine zentrale Rolle. Eine Hemmung der Aldosteronwirkung bessert Belastbarkeit und Prognose herzinsuffizienter Patienten. \u00dcber den 2005 eingef\u00fchrten (selektiv an den Mineralokortikoid-Rezeptor bindenden) Aldosteron-Antagonisten Eplerenon (Inspra\u00ae; Pfizer) haben wir anl\u00e4sslich seiner Zulassung berichtet (1,\u00a02). Die Zulassungsstudie [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","footnotes":""},"categories":[199,866],"tags":[881,882,883,330],"class_list":["post-1755","post","type-post","status-publish","format-standard","hentry","category-jahr-2011-band-45","category-monat-7","tag-emphasis-hf-studie","tag-ephesus-studie","tag-eplerenon","tag-herzinsuffizienz"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Eplerenon: Neuer Therapiestandard bei Herzinsuffizienz NYHA II?<\/title>\n<meta name=\"description\" content=\"In der Entstehungskaskade der Herzinsuffizienz spielt der Hyperaldosteronismus eine zentrale ...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/eplerenon-neuer-therapiestandard-bei-herzinsuffizienz-nyha-ii\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eplerenon: Neuer Therapiestandard bei Herzinsuffizienz NYHA II?\" \/>\n<meta property=\"og:description\" content=\"In der Entstehungskaskade der Herzinsuffizienz spielt der Hyperaldosteronismus eine zentrale ...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/eplerenon-neuer-therapiestandard-bei-herzinsuffizienz-nyha-ii\/\" \/>\n<meta property=\"og:site_name\" content=\"Der Arzneimittelbrief\" \/>\n<meta property=\"article:publisher\" content=\"http:\/\/www.facebook.com\/derarzneimittelbrief.de\" \/>\n<meta property=\"article:published_time\" content=\"2014-03-17T13:01:42+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/www.der-arzneimittelbrief.de\/_images\/link.jpeg\" \/>\n<meta name=\"author\" content=\"henk-amb\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"henk-amb\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"5\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/eplerenon-neuer-therapiestandard-bei-herzinsuffizienz-nyha-ii\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/eplerenon-neuer-therapiestandard-bei-herzinsuffizienz-nyha-ii\\\/\"},\"author\":{\"name\":\"henk-amb\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/2e7981c97826a4941311e607c145d937\"},\"headline\":\"Eplerenon: Neuer Therapiestandard bei Herzinsuffizienz NYHA II?\",\"datePublished\":\"2014-03-17T13:01:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/eplerenon-neuer-therapiestandard-bei-herzinsuffizienz-nyha-ii\\\/\"},\"wordCount\":985,\"image\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/eplerenon-neuer-therapiestandard-bei-herzinsuffizienz-nyha-ii\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/_images\\\/link.jpeg\",\"keywords\":[\"EMPHASIS-HF-Studie\",\"EPHESUS-Studie\",\"Eplerenon\",\"Herzinsuffizienz\"],\"articleSection\":[\"Jahr 2011 Band 45\",\"Monat 7\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/eplerenon-neuer-therapiestandard-bei-herzinsuffizienz-nyha-ii\\\/\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/eplerenon-neuer-therapiestandard-bei-herzinsuffizienz-nyha-ii\\\/\",\"name\":\"Eplerenon: Neuer Therapiestandard bei Herzinsuffizienz NYHA II?\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/eplerenon-neuer-therapiestandard-bei-herzinsuffizienz-nyha-ii\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/eplerenon-neuer-therapiestandard-bei-herzinsuffizienz-nyha-ii\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/_images\\\/link.jpeg\",\"datePublished\":\"2014-03-17T13:01:42+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/2e7981c97826a4941311e607c145d937\"},\"description\":\"In der Entstehungskaskade der Herzinsuffizienz spielt der Hyperaldosteronismus eine zentrale ...\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/eplerenon-neuer-therapiestandard-bei-herzinsuffizienz-nyha-ii\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/eplerenon-neuer-therapiestandard-bei-herzinsuffizienz-nyha-ii\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/eplerenon-neuer-therapiestandard-bei-herzinsuffizienz-nyha-ii\\\/#primaryimage\",\"url\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/_images\\\/link.jpeg\",\"contentUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/_images\\\/link.jpeg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/eplerenon-neuer-therapiestandard-bei-herzinsuffizienz-nyha-ii\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eplerenon: Neuer Therapiestandard bei Herzinsuffizienz NYHA II?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\",\"name\":\"Der Arzneimittelbrief\",\"description\":\"Unabh\u00e4ngige Arzneimittelinformationen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/2e7981c97826a4941311e607c145d937\",\"name\":\"henk-amb\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g\",\"caption\":\"henk-amb\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Eplerenon: Neuer Therapiestandard bei Herzinsuffizienz NYHA II?","description":"In der Entstehungskaskade der Herzinsuffizienz spielt der Hyperaldosteronismus eine zentrale ...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/eplerenon-neuer-therapiestandard-bei-herzinsuffizienz-nyha-ii\/","og_locale":"de_DE","og_type":"article","og_title":"Eplerenon: Neuer Therapiestandard bei Herzinsuffizienz NYHA II?","og_description":"In der Entstehungskaskade der Herzinsuffizienz spielt der Hyperaldosteronismus eine zentrale ...","og_url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/eplerenon-neuer-therapiestandard-bei-herzinsuffizienz-nyha-ii\/","og_site_name":"Der Arzneimittelbrief","article_publisher":"http:\/\/www.facebook.com\/derarzneimittelbrief.de","article_published_time":"2014-03-17T13:01:42+00:00","og_image":[{"url":"http:\/\/www.der-arzneimittelbrief.de\/_images\/link.jpeg","type":"","width":"","height":""}],"author":"henk-amb","twitter_misc":{"Verfasst von":"henk-amb","Gesch\u00e4tzte Lesezeit":"5\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/eplerenon-neuer-therapiestandard-bei-herzinsuffizienz-nyha-ii\/#article","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/eplerenon-neuer-therapiestandard-bei-herzinsuffizienz-nyha-ii\/"},"author":{"name":"henk-amb","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/2e7981c97826a4941311e607c145d937"},"headline":"Eplerenon: Neuer Therapiestandard bei Herzinsuffizienz NYHA II?","datePublished":"2014-03-17T13:01:42+00:00","mainEntityOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/eplerenon-neuer-therapiestandard-bei-herzinsuffizienz-nyha-ii\/"},"wordCount":985,"image":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/eplerenon-neuer-therapiestandard-bei-herzinsuffizienz-nyha-ii\/#primaryimage"},"thumbnailUrl":"http:\/\/www.der-arzneimittelbrief.de\/_images\/link.jpeg","keywords":["EMPHASIS-HF-Studie","EPHESUS-Studie","Eplerenon","Herzinsuffizienz"],"articleSection":["Jahr 2011 Band 45","Monat 7"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/eplerenon-neuer-therapiestandard-bei-herzinsuffizienz-nyha-ii\/","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/eplerenon-neuer-therapiestandard-bei-herzinsuffizienz-nyha-ii\/","name":"Eplerenon: Neuer Therapiestandard bei Herzinsuffizienz NYHA II?","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/eplerenon-neuer-therapiestandard-bei-herzinsuffizienz-nyha-ii\/#primaryimage"},"image":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/eplerenon-neuer-therapiestandard-bei-herzinsuffizienz-nyha-ii\/#primaryimage"},"thumbnailUrl":"http:\/\/www.der-arzneimittelbrief.de\/_images\/link.jpeg","datePublished":"2014-03-17T13:01:42+00:00","author":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/2e7981c97826a4941311e607c145d937"},"description":"In der Entstehungskaskade der Herzinsuffizienz spielt der Hyperaldosteronismus eine zentrale ...","breadcrumb":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/eplerenon-neuer-therapiestandard-bei-herzinsuffizienz-nyha-ii\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/eplerenon-neuer-therapiestandard-bei-herzinsuffizienz-nyha-ii\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/eplerenon-neuer-therapiestandard-bei-herzinsuffizienz-nyha-ii\/#primaryimage","url":"http:\/\/www.der-arzneimittelbrief.de\/_images\/link.jpeg","contentUrl":"http:\/\/www.der-arzneimittelbrief.de\/_images\/link.jpeg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/eplerenon-neuer-therapiestandard-bei-herzinsuffizienz-nyha-ii\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/"},{"@type":"ListItem","position":2,"name":"Eplerenon: Neuer Therapiestandard bei Herzinsuffizienz NYHA II?"}]},{"@type":"WebSite","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/","name":"Der Arzneimittelbrief","description":"Unabh\u00e4ngige Arzneimittelinformationen","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Person","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/2e7981c97826a4941311e607c145d937","name":"henk-amb","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/secure.gravatar.com\/avatar\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g","caption":"henk-amb"}}]}},"_links":{"self":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/1755","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/comments?post=1755"}],"version-history":[{"count":1,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/1755\/revisions"}],"predecessor-version":[{"id":1756,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/1755\/revisions\/1756"}],"wp:attachment":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/media?parent=1755"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/categories?post=1755"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/tags?post=1755"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}